GlassScriptPhysician profile
David C Manfredi
NPI 1982675278
$530.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $110 · 2021: $23.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $252.84 | 2019-2020 | |
| Amarin Pharma, INC. | $63.75 | 2019-2020 | |
| Novo Nordisk INC | $61.68 | 2019 | |
| Grifols USA, LLC | $25.01 | 2019 | |
| Abbott Laboratories | $24.24 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.59 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.62 | 2020 | |
| Glaxosmithkline, LLC. | $12.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Manfredi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.